LiDCO Group plc : Exercise of share options

Exercise of share options

22 June 2012

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, announces that further to the exercise of share options by an employee, 21,000 new ordinary shares of 0.5p each in the Company ("New Ordinary Shares") have been issued.

Application has been made for 21,000 New Ordinary Shares to be admitted to trading on AIM, which will rank pari passu with Company's existing Ordinary Shares, and admission is expected to become effective on 28 June 2012 ("Admission").

Following admission of the New Ordinary Shares, the Company will have 174,336,304 Ordinary Shares in issue with each share carrying the right to one vote. There are no shares held in Treasury. The total number of voting rights in LiDCO is therefore 174,336,304. This number may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or a change in their interest in, LiDCO, under the Disclosure and Transparency Rules.

For further information, please contact:

LiDCO Group Plc
Terry O'Brien (CEO)	Tel: +44 (0)20 7749 1500
Paul Clifford (Finance Director)
Theresa Wallis (Chairman)	www.lidco.com
FinnCap
Geoff Nash / Henrik Persson Stephen Norcross (broking)	Tel: +44 (0)20 7600 1658 www.finncap.com

Media enquiries:

Abchurch
Sarah Hollins / Adam Michael / Joanne Shears / Jamie Hooper	Tel: +44 (0) 20 7398 7719
jamie.hooper@abchurch-group.com	www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. These benefits are:

• Early and rapid warning of change
• Clear indication of therapeutic route: fluid or drug
• Quantification of hemodynamic response, particularly stroke volume
• Permits more effective delivery of fluids - the right amount at the right time
• Advanced hemodynamic care has been shown to contribute to:
  - Reduced morbidity and complications, length of stay & overall cost of care

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.

* LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

* LiDCO's Distribution Network:

The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.

Partner Area